Morningstar - Ainsworth Game Technology Ltd. (AGI) Placing Ainsworth Game Technology Under Review

Report

Morningstar

Daniel Ragonese

EUR 100.00 For Business Accounts Only

Placing Ainsworth Game Technology Under Review

We are placing Ainsworth Game Technology under review following todayâ€™s severe earnings downgrade. Management has once again failed to deliver on expectations, slashing earnings guidance for the second half of fiscal 2018. Profit before tax, or PBT, in the second half of fiscal 2018 is now expected to be around AUD 20 million, which is less than half the prior guidance of modestly ahead of the AUD 42 million pcp. Management now expect full-year PBT of approximately AUD 36 million, down 37% on la...

04/05/2018 14 EN

Underlying

Ainsworth Game Technology Ltd.

Ainsworth Game Technology is a gaming machine developer, designer and manufacturer operating in local and global markets. Co. is engaged in the design, development, production, lease, sale and servicing of gaming machines and other related equipment and services. Co. provides its product within both land based and on-line gaming markets, including social gaming and licensed Real Money gambling markets. Co.'s game brands include Mustang Money 2™, Thunder Cash™, Twice The Money™ and Cash Cave™.

See profile

AU000000AGI3 Australian Securities Exchange Australia

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Daniel Ragonese

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

TheScreener

A double requalification allows AINSWORTH GAME TECH.LTD. to improve to Slightly Positive

AINSWORTH GAME TECH.LTD. (AU), a company active in the Gambling industry, has received a double requalification by the independent financial analyst theScreener. Its fundamental valuation is now 3 out of 4 stars while its market behaviour can be considered as defensive. theScreener believes that the gain of a star(s) and an improvement in the market risk perception allows upgrading the general evaluation to Slightly Positive. As of the analysis date February 28, 2020, the closing price was AUD 0.70 and its potential was estimated at AUD 0.83.

Free Trial

February 29, 2020 February 29, 2020 6 EN

Fundamental Research

Feasibility Study Results in December to be a Catalyst for this Junior

EUR 17.06

November 25, 2019 November 25, 2019 14 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Placing Ainsworth Game Technology Under Review

Monthly LMI Update Independent Investment Research

A double requalification allows AINSWORTH GAME TECH.LTD. to improve to Slightly Positive

Feasibility Study Results in December to be a Catalyst for this Junior

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe